5F-PB-22 (5F-QUPIC or quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate) is a
designer drug which acts as a
cannabinoid agonist.[2] The structure of 5F-PB-22 appears to have been designed with an understanding of
structure–activity relationships within the indole class of cannabinoids.[3]
As of October 2015 5F-PB-22 is a controlled substance in China.[5]
In January 2014, 5F-PB-22 was designated as a
Schedule I controlled substance in the United States after several deaths were associated with its use.[6][7]
In the United Kingdom, 5F-PB-22 is now classified and controlled as a
Class B drug, following the November 2016 amendment to the
Misuse of Drugs Act 1971. Several other synthetic cannabinoids structurally related to
JWH-018, like 5F-PB-22, were also classified in this amendment.[8]
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from
the original on 1 October 2015. Retrieved 1 October 2015.
^Trecki J, Gerona RR, Schwartz MD (July 2015). "Synthetic Cannabinoid-Related Illnesses and Deaths". The New England Journal of Medicine. 373 (2): 103–7.
doi:
10.1056/NEJMp1505328.
PMID26154784.